Western Drugmakers Turn to China as Patent Cliff Drives Multibillion-Dollar Deals
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Novartis will pay Abogen Biosciences $575 million upfront and up to $7.2 billion in milestones for global rights to an early-stage mRNA autoimmune therapy. The deal follows Novo’s agreement worth up to $2.6 billion with Hengrui Pharma for a weekly GLP-1/GIP pill.
Continue in the app — vote & join in ➔Source: CNBC Top News · via ahirlevel.hu